CareDx Inc (CDNA) - Net Assets
Based on the latest financial reports, CareDx Inc (CDNA) has net assets worth $313.54 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($411.06 Million) and total liabilities ($97.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CDNA intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $313.54 Million |
| % of Total Assets | 76.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -34.94% |
| 10-Year Change | 1433.83% |
| Growth Volatility | 77.39 |
CareDx Inc - Net Assets Trend (2012–2025)
This chart illustrates how CareDx Inc's net assets have evolved over time, based on quarterly financial data. See CDNA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for CareDx Inc (2012–2025)
The table below shows the annual net assets of CareDx Inc from 2012 to 2025. For live valuation and market cap data, see CDNA stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $303.10 Million | -19.91% |
| 2024-12-31 | $378.43 Million | +44.81% |
| 2023-12-31 | $261.33 Million | -39.35% |
| 2022-12-31 | $430.91 Million | -7.51% |
| 2021-12-31 | $465.88 Million | +67.78% |
| 2020-12-31 | $277.68 Million | +180.48% |
| 2019-12-31 | $99.00 Million | +3.20% |
| 2018-12-31 | $95.93 Million | +1711.15% |
| 2017-12-31 | $-5.95 Million | -130.13% |
| 2016-12-31 | $19.76 Million | -33.00% |
| 2015-12-31 | $29.49 Million | -28.58% |
| 2014-12-31 | $41.30 Million | +127.41% |
| 2013-12-31 | $-150.67 Million | -2.36% |
| 2012-12-31 | $-147.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CareDx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 57874500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $50.00K | 0.02% |
| Other Comprehensive Income | $-5.51 Million | -1.82% |
| Other Components | $1.04 Billion | 344.41% |
| Total Equity | $303.10 Million | 100.00% |
CareDx Inc Competitors by Market Cap
The table below lists competitors of CareDx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Intellect Design Arena Limited
NSE:INTELLECT
|
$1.13 Billion |
|
Xinjiang Communications Construction Group Co Ltd Class A
SHE:002941
|
$1.13 Billion |
|
Danya Cebus
TA:DNYA
|
$1.13 Billion |
|
AS LHV GROUP EO -10
F:ASU0
|
$1.13 Billion |
|
Hubei Biocause Pharmaceutical
SHE:000627
|
$1.13 Billion |
|
Lindab International AB
ST:LIAB
|
$1.13 Billion |
|
Suofeiya Home Collection Co Ltd
SHE:002572
|
$1.13 Billion |
|
Procter & Gamble Health Limited
NSE:PGHL
|
$1.13 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CareDx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 378,433,000 to 303,101,000, a change of -75,332,000 (-19.9%).
- Net loss of 21,354,000 reduced equity.
- Share repurchases of 87,768,000 reduced equity.
- Other comprehensive income increased equity by 3,054,000.
- Other factors increased equity by 30,736,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.35 Million | -7.05% |
| Share Repurchases | $87.77 Million | -28.96% |
| Other Comprehensive Income | $3.05 Million | +1.01% |
| Other Changes | $30.74 Million | +10.14% |
| Total Change | $- | -19.91% |
Book Value vs Market Value Analysis
This analysis compares CareDx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-19.97 | $26.18 | x |
| 2013-12-31 | $-20.44 | $26.18 | x |
| 2014-12-31 | $4.45 | $26.18 | x |
| 2015-12-31 | $2.49 | $26.18 | x |
| 2016-12-31 | $1.18 | $26.18 | x |
| 2017-12-31 | $-0.26 | $26.18 | x |
| 2018-12-31 | $2.69 | $26.18 | x |
| 2019-12-31 | $2.35 | $26.18 | x |
| 2020-12-31 | $5.97 | $26.18 | x |
| 2021-12-31 | $8.92 | $26.18 | x |
| 2022-12-31 | $8.08 | $26.18 | x |
| 2023-12-31 | $4.86 | $26.18 | x |
| 2024-12-31 | $6.68 | $26.18 | x |
| 2025-12-31 | $5.69 | $26.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CareDx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.62%
- • Asset Turnover: 0.92x
- • Equity Multiplier: 1.36x
- Recent ROE (-7.05%) is above the historical average (-29.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -24.74% | 2.07x | 0.00x | $9.66 Million |
| 2013 | 0.00% | -16.03% | 2.24x | 0.00x | $11.53 Million |
| 2014 | 1.89% | 2.86% | 0.45x | 1.48x | $-3.35 Million |
| 2015 | -46.47% | -48.70% | 0.51x | 1.89x | $-16.66 Million |
| 2016 | -202.59% | -97.14% | 0.53x | 3.94x | $-41.42 Million |
| 2017 | 0.00% | -114.79% | 0.58x | 0.00x | $-54.86 Million |
| 2018 | -48.74% | -61.06% | 0.59x | 1.36x | $-56.35 Million |
| 2019 | -22.19% | -17.29% | 0.84x | 1.53x | $-31.87 Million |
| 2020 | -6.74% | -9.74% | 0.52x | 1.33x | $-46.48 Million |
| 2021 | -6.58% | -10.34% | 0.52x | 1.22x | $-77.25 Million |
| 2022 | -17.78% | -23.81% | 0.59x | 1.26x | $-119.70 Million |
| 2023 | -72.81% | -67.88% | 0.60x | 1.79x | $-216.42 Million |
| 2024 | 13.89% | 15.74% | 0.68x | 1.30x | $14.71 Million |
| 2025 | -7.05% | -5.62% | 0.92x | 1.36x | $-51.66 Million |
Industry Comparison
This section compares CareDx Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $699,550,940
- Average return on equity (ROE) among peers: -122.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CareDx Inc (CDNA) | $313.54 Million | 0.00% | 0.31x | $1.13 Billion |
| Agilent Technologies Inc (A) | $4.63 Billion | -22.30% | 0.77x | $35.96 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $976.24K | -188.19% | 0.03x | $6.13 Million |
| Applied DNA Sciences Inc (APDN) | $8.97 Million | -77.97% | 0.43x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.88 Million | -205.65% | 3.66x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.07 Million | 0.00% | 0.00x | $3.77 Million |
| Biocept Inc. (BIOCQ) | $8.86 Million | -362.16% | 2.48x | $525.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $4.36 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $63.90 Million |
| Check Cap Ltd (CHEK) | $5.91 Million | -165.47% | 0.34x | $9.42 Million |
About CareDx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart tr… Read more